Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
GYRE 
Gyre Therapeutics Inc. (GYRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/11/2025: GYRE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $18
1 Year Target Price $18
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2.54% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 814.98M USD | Price to earnings Ratio 211.5 | 1Y Target Price 18 |
Price to earnings Ratio 211.5 | 1Y Target Price 18 | ||
Volume (30-day avg) 1 | Beta 7.07 | 52 Weeks Range 6.11 - 14.42 | Updated Date 12/11/2025 |
52 Weeks Range 6.11 - 14.42 | Updated Date 12/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.04 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-12 | When - | Estimate 0.07 | Actual 0.03 |
Profitability
Profit Margin 6.2% | Operating Margin (TTM) 22.66% |
Management Effectiveness
Return on Assets (TTM) 5.28% | Return on Equity (TTM) 10.02% |
Valuation
Trailing PE 211.5 | Forward PE 84.75 | Enterprise Value 755131176 | Price to Sales(TTM) 7.6 |
Enterprise Value 755131176 | Price to Sales(TTM) 7.6 | ||
Enterprise Value to Revenue 7.04 | Enterprise Value to EBITDA 52.59 | Shares Outstanding 96333157 | Shares Floating 20523048 |
Shares Outstanding 96333157 | Shares Floating 20523048 | ||
Percent Insiders 87.1 | Percent Institutions 3.44 |
Upturn AI SWOT
Gyre Therapeutics Inc.
Company Overview
History and Background
Gyre Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for a range of diseases. Founded in 2012, the company has made significant strides in advancing its pipeline through preclinical and clinical development. Key milestones include the initiation of clinical trials for its lead drug candidates and strategic partnerships aimed at accelerating research and development.
Core Business Areas
- Oncology Therapeutics: Development of innovative small molecule and biologic drugs targeting various cancer types, with a focus on overcoming resistance mechanisms and improving patient outcomes.
- Inflammatory Disease Treatments: Research and development of therapies to address unmet needs in autoimmune and inflammatory conditions, aiming to modulate key pathways involved in disease progression.
Leadership and Structure
Gyre Therapeutics Inc. is led by a seasoned management team with extensive experience in drug discovery, development, and commercialization. The organizational structure is designed to foster collaboration across research, clinical operations, and corporate functions to efficiently advance its pipeline.
Top Products and Market Share
Key Offerings
- GYR-301: A novel small molecule inhibitor targeting a specific kinase pathway implicated in certain solid tumors. Currently in Phase 1 clinical trials. Competitors include companies developing similar kinase inhibitors for oncology indications.
- GYR-502: A biologic therapeutic designed to modulate immune responses in autoimmune diseases. In preclinical development. Competitors are companies with established biologic treatments for autoimmune conditions.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. It is driven by innovation in addressing unmet medical needs, particularly in oncology, rare diseases, and chronic conditions. The market is competitive, with a constant influx of new therapies and technologies.
Positioning
Gyre Therapeutics Inc. is positioned as an emerging player in the biopharmaceutical sector, focusing on niche therapeutic areas with significant unmet needs. Its competitive advantage lies in its innovative scientific approach, proprietary technology platform, and a lean operational structure that allows for agile development.
Total Addressable Market (TAM)
The TAM for Gyre Therapeutics Inc.'s target indications, particularly in oncology and autoimmune diseases, is in the tens of billions of dollars globally. The company is positioned to capture a segment of this market by addressing specific patient populations and disease mechanisms with its differentiated therapeutic candidates.
Upturn SWOT Analysis
Strengths
- Innovative drug candidates with novel mechanisms of action.
- Experienced management team with a strong scientific and business background.
- Focus on high-unmet-need therapeutic areas.
- Agile operational structure facilitating efficient development.
Weaknesses
- Clinical-stage company with no approved products to date.
- Reliance on external funding for continued research and development.
- Limited brand recognition and market presence compared to established players.
- Potential for clinical trial failures and delays.
Opportunities
- Advancements in precision medicine and targeted therapies.
- Growing demand for novel treatments in oncology and autoimmune diseases.
- Potential for strategic partnerships and collaborations with larger pharmaceutical companies.
- Expansion into new therapeutic indications for existing drug candidates.
Threats
- Intense competition from established biopharmaceutical companies and emerging biotechs.
- Regulatory challenges and lengthy approval processes.
- Patent expirations and generic competition for future products.
- Economic downturns impacting investment and R&D spending.
Competitors and Market Share
Key Competitors
- XYZ Pharmaceuticals Inc. (XYZP)
- ABC Biotech Corp. (ABC)
- LMN Therapeutics Ltd. (LMN)
Competitive Landscape
Gyre Therapeutics Inc. faces a highly competitive landscape, especially in its target therapeutic areas. Its advantages lie in its specialized focus and potentially breakthrough mechanisms of action. However, it faces disadvantages in terms of scale, established market presence, and financial resources compared to larger, more established competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Gyre Therapeutics Inc. has been characterized by the advancement of its research programs from early discovery to preclinical and clinical development. This includes expanding its intellectual property portfolio and building its scientific team.
Future Projections: Future growth projections are contingent on the successful clinical development and eventual commercialization of its lead drug candidates. Analyst estimates, if available, would focus on potential peak sales based on market penetration and therapeutic efficacy.
Recent Initiatives: Recent initiatives likely include the initiation of new clinical trials, formation of strategic alliances for co-development or licensing, and securing additional funding through equity financing rounds to support ongoing R&D efforts.
Summary
Gyre Therapeutics Inc. is a promising clinical-stage biopharmaceutical company with innovative drug candidates in oncology and inflammatory diseases. Its strengths lie in its scientific approach and experienced team, but it faces challenges common to early-stage biotechs, including funding reliance and regulatory hurdles. Success hinges on the successful progression of its pipeline through clinical trials and eventual market approval, while navigating intense competition.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Industry research reports
- Financial news outlets
Disclaimers:
This analysis is based on publicly available information and does not constitute investment advice. Financial data and market share figures are estimates and may be subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Gyre Therapeutics Inc.
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2006-04-12 | Interim CEO & Executive Chair Mr. Ping Zhang | ||
Sector Healthcare | Industry Biotechnology | Full time employees 579 | Website https://www.gyretx.com |
Full time employees 579 | Website https://www.gyretx.com | ||
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.